Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07093775
Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score
Sponsor: Gangnam Severance Hospital
View on ClinicalTrials.gov
Summary
To evaluated the prognostic significance of tumor grade in patients with node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2-negative breast cancers treated according to RS-guided strategies.
Official title: Prognostic Implication of Tumor Grade in Patients With Node-negative Breast Cancer Aged ≤ 50 Years With 21-gene Recurrence Scores of 11-25
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
OBSERVATIONAL
Enrollment
4000
Start Date
2025-07
Completion Date
2026-03
Last Updated
2025-07-30
Healthy Volunteers
No
Conditions
Interventions
OTHER
Tumor grade (I or II vs. III)
We compared the prognosis according to the tumor grade stratified by 21-gene recurrence score